Epipodophyllotoxin-related leukemia Identification new subset secondary leukemia Thirty-seven children adults nonlymphocytic leukemia administration chemotherapy variety hematologic solid malignancies secondary leukemia patients secondary leukemia treatment agents following shorter latency period predominance monocytic myelomonocytic features frequent cytogenetic abnormalities Patients epipodophyllotoxin risk secondary leukemia features syndrome secondary leukemia agents 